Christopher J. Czura, PhD

Vice President, Scientific Affairs, The Feinstein Institute for Medical Research

Executive Editor, Molecular Medicine, Boas Marks Pavilion
Phone: 516-562-2110
Fax: 516-562-2356

About the Investigator

Christopher J. Czura, PhD, is vice president of the Feinstein Institute for Medical Research, executive publisher of the Feinstein Institute Press’ international, peer-reviewed journals Molecular Medicine and Bioelectronic Medicine, executive producer of the Merinoff Conference Series, and chief financial officer for the Elmezzi Graduate School of Molecular Medicine. Dr. Czura provides oversight of the Institute’s daily operations and $95 million annual budget.  He collaborates with the president of the Institute to develop and execute strategic plans, and is committed to building successful programs that nurture the collaborative and interactive environment of the Feinstein Institute. He leads project teams in the design and oversight of construction of new laboratory facilities and renovation projects.

A molecular biologist by training, Dr. Czura’s research interests focus on autonomic neural regulation of hemostasis and inflammation.  He received his B.S. in biotechnology from William Paterson University in 1996 and a doctoral degree in molecular microbiology from Stony Brook University in 2009.  He is author or co-author of approximately 80 peer-reviewed publications, book chapters and meeting abstracts, and co-inventor on a patent that describes vagus nerve stimulation to control hemorrhage.

Research Focus

Dr. Czura began his research career in the laboratory of Kevin J. Tracey, MD, studying the mechanisms of pathological inflammation.  His early work focused on validating HMGB1 as a therapeutic target, and gaining a broader understanding of its molecular mechanisms of disease pathogenesis.  Dr. Czura has also studied the inflammatory reflex, a neural mechanism through which the central nervous system detects and regulates immune responses to infection and injury.

More recently, Dr. Czura and his colleagues Kevin J. Tracey, MD, and Jared Huston, MD, have made discoveries in the field of bioelectronic medicine, a new field of technology that uses electrical impulses to regulate neural activity to cure disease.  His primary work in this field led to the discovery of the “neural tourniquet,” a field of technology that uses electrical nerve stimulation to control traumatic hemorrhage.  Dr. Czura’s current research focuses on the molecular mechanisms of the neural tourniquet, and the development of new devices to activate this novel mechanism to control bleeding.

  1. “Vagus nerve stimulation regulates hemostasis in swine.” Czura CJ, Schultz A, Kaipel M, Khadem A, Huston JM, Pavlov VA, Redl H, Tracey KJ. Shock. 2010 Jun;33(6):608-13.
  2. “Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis.”  Huston JM, Gallowitsch-Puerta M, Ochani M, Ochani K, Yuan R, Rosas-Ballina M, Ashok M, Goldstein RS, Chavan S, Pavlov VA, Metz CN, Yang H, Czura CJ, Wang H, Tracey KJ. Crit Care Med. 2007 Dec;35(12):2762-8.
  3. “Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis.”  Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin X, Levi J, Parrish WR, Rosas-Ballina M, Czura CJ, Larosa GJ, Miller EJ, Tracey KJ, Al-Abed Y. Crit Care Med. 2007 Apr;35(4):1139-44.
  4. “Role of HMGB1 in apoptosis-mediated sepsis lethality.” Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H. J Exp Med. 2006 Jul 10;203(7):1637-42.
  5. “Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis.” Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov VA, Gallowitsch-Puerta M, Ashok M, Czura CJ, Foxwell B, Tracey KJ, Ulloa L. J Exp Med. 2006 Jul 10;203(7):1623-8.
  6. “Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia.”  Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, Lee DC, Ward MF, Bruchfeld AN, Wang H, Lesser ML, Church AL, Litroff AH, Sama AE, Tracey KJ. Shock. 2006 Jun;25(6):571-4.
  7. “Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia.” Pavlov VA, Ochani M, Gallowitsch-Puerta M, Ochani K, Huston JM, Czura CJ, Al-Abed Y, Tracey KJ.  Proc Natl Acad Sci USA. 2006 Mar 28;103(13):5219-23.
  8. “Autonomic neural regulation of immunity.”  Czura CJ, Tracey KJ. J Intern Med. 2005 Feb;257(2):156-66.
  9. HMGB1 in the immunology of sepsis (not septic shock) and arthritis. Czura CJ, Yang H, Amella CA, Tracey KJ. Adv Immunol. 2004;84:181-200.
  10. “Reversing established sepsis with antagonists of endogenous high-mobility group box 1.” Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ. Proc Natl Acad Sci USA. 2004 Jan 6;101(1):296-301
  11. “High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.” Czura CJ, Yang H, Tracey KJ. J Infect Dis. 2003 Jun 15;187 Suppl 2:S391-6.
  12. “Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.” Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ.  Nature. 2003 Jan 23;421(6921):384-8.
  13. “Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation.”  Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ.  Proc Natl Acad Sci USA. 2002 Sep 17;99(19):12351-6.
  14. “Pharmacological stimulation of the cholinergic antiinflammatory pathway.” Bernik TR, Friedman SG, Ochani M, DiRaimo R, Ulloa L, Yang H, Sudan S, Czura CJ, Ivanova SM, Tracey KJ.  J Exp Med. 2002 Mar 18;195(6):781-8.
  15. “Mind over immunity.” Tracey KJ, Czura CJ, Ivanova S. FASEB J. 2001 Jul;15(9):1575-6.

View more at PubMed